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Weight change during chemotherapy changes
the prognosis in non metastatic breast
cancer for the worse
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Abstract
Background: Weight change during chemotherapy is reported to be associated with a worse prognosis in breast
cancer patients, both with weight gain and weight loss. However, most studies were conducted prior to the
common use of anthracycline-base chemotherapy and on North American populations with a mean BMI classified
as overweight. Our study was aimed to evaluate the prognostic value of weight change during anthracycline-
based chemotherapy on non metastatic breast cancer (European population) with a long term follow-up.
Methods: Patients included 111 women diagnosed with early stage breast cancer and locally advanced breast
cancer who have been treated by anthracycline-based chemotherapy regimen between 1976 and 1989. The
relative percent weight variation (WV) between baseline and postchemotherapy treatment was calculated and
categorized into either weight change (WV > 5%) or stable (WV < 5%). The median follow-up was 20.4 years
[19.4 - 27.6]. Cox proportional hazard models were used to evaluate any potential association of weight change
and known prognostic factors with the time to recurrence and overall survival.
Results: Baseline BMI was 24.4 kg/m2 [17.1 - 40.5]. During chemotherapy treatment, 31% of patients presented a
notable weight variation which was greater than 5% of their initial weight.
In multivariate analyses, weight change (> 5%) was positively associated with an increased risk of both recurrence
(RR 2.28; 95% CI: 1.29-4.03) and death (RR 2.11; 95% CI: 1.21-3.66).
Conclusions: Our results suggest that weight change during breast-cancer chemotherapy treatment may be
related to poorer prognosis with higher reccurence and higher mortality in comparison to women who
maintained their weight.
Background
Age, tumour size, axillary node status, histological
tumour type and standardized pathological grade are
accepted as well-defined prognostic factors in breast
cancer [1]. Various studies have also reported striking
associations between overweight or obesity at breast
cancer diagnosis and poorer prognosis with higher dis-
tant recurrence and mortality (for review [2]). As
emphasized by Goodwin et al. [3], the risk of recurrence
and death was respectively 1.78 (95% CI: 1.50-2.11) and
1.36 (95% CI: 1.19-1.55) times greater for obese patients
over a 10 years follow-up period.
Moreover, numerous studies reported a weight gain
after breast cancer development that might be attributa-
ble to the effects of some treatment regimens [4,5].
Weight gain in breast cancer patients has been asso-
ciated with anti-neoplastic chemotherapy in the majority
of studies. Previous studies suggest that weight gain is
more pronounced among premenopausal women and
among those who were treated with a multiagent regi-
men [6,7]. However, few reports have not observed
increased weight gain during chemotherapy [5,8,9], in
particular with anthracycline-containing regimens [10,11]
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widely recognized as the gold standard treatment of
women with breast cancer.
There is also substantial evidence that weight change
during chemotherapy may be associated with a worse
prognosis for the cancer patient, both with weight gain
[12] and weight loss [13]. The findings reported by the
few studies which have explored the prognostic value of
weight gain after a diagnosis of breast cancer are mixed:
four studies reported that weight gain was associated
with a decreased overall survival and increased recur-
rence risk [8,14-16] whereas five others failed to report
such associations [10,9,17]. Only one recent study
reported some evidence that women with early breast
cancer, who had a weight loss during treatment, were at
higher risk of recurrence and death compared to
women with no weight variation [18]. These discrepan-
cies may be attributable to the heterogeneity of the
methods implemented in the different studies, including
the duration of post-diagnosis weight assessment, the
definition of the prognostic outcomes with a short med-
ian of follow-up and treatment (chemotherapy and/or
hormonotherapy...). The majority of the previous studies
were conducted before anthracycline-base chemotherapy
was commonly used. Additionally all the aforementioned
studies focused on north American populations with a
mean Body Mass Index (BMI) at breast cancer diagnosis
classified as overweight [14,19]. However no data is
available on the prognostic impact of weight change
during chemotherapy treatment in European breast can-
cer patients who presented a notably lower BMI [20].
Our study thus investigated the prognostic value
(death and recurrence) of weight variation during
anthracycline-based chemotherapy treatment of breast
cancer in a French population with a long-term follow-
up. We also verified the association of weight at breast
cancer diagnosis with survival.
Methods
Population
A retrospective chart review was performed using data
from hospital medical records on all women with early
stage breast cancer and locally advanced breast cancer
who were treated at Jean Perrin Center (Clermont-
Ferrand) between 1976 and 1989 in order to have at
least 20 years of follow-up for the study. Among the
709 women treated with chemotherapy treatment for
breast cancer, 111 women were included in the analysis.
The study was approved by the Inter-regional Ethics
Committee of the Rhône -Alpes-Auvergne Clinical
Investigation Center (N°IRB5044). Subjects were selected
if they had histologically confirmed stage I-III breast
cancer, and received chemotherapy under the anthracy-
cline-based chemotherapy regimen. Patients were
excluded from this review if weight assessment did not
include at least measurements at baseline and at the end
of chemotherapy, if they had distant metastasis at diag-
nosis or a history of another malignancy.
Weight measurements
Weight was measured at the hospital by a nurse at the
beginning of treatment and in the last chemotherapy
cycle. The BMI was calculated by dividing weight (kg)
by height (m) squared. The different subclasses
of patients were categorized as followed: underweight
(< 18.5), normal (18.5 - 25), overweight (25 - 29.9) or
obese (≥ 30). The median BMI being of 24.4 kg/m2
rounded down to 24 kg/m2 was used to median-split
the population, i.e. categorized women as having BMI
less than 24, or more than 24 kg/m2.
A number of studies suggest that a 5% change in body
weight is clinically meaningful [5]. Weight variations
(WV) were calculated as the relative percent weight
changes between weight measurement from baseline to
post-chemotherapy treatment ((baseline weight - weight
after chemotherapy)/baseline weight × 100). WV were
categorized accordingly into weight change (WV > 5%)
or stable (WV < 5%). The weight changing group
(WV > 5%) combined women who lost weight (defined
by a relative weight loss >5% between weight measure-
ment from baseline to post-chemotherapy treatment)
and women who gained weight (defined by a relative
weight gain > 5%).
Covariates
Information on the age of patients, menopausal status,
hormonal receptors, tumour stage, nodal involvement,
Scarff-Bloom-Richardson (SBR) grade, and on treatment
received before and after chemotherapy were obtained
from reviewing patients’ medical records. We used the
Tumour- Node-Metastasis (TNM) classification of stage
of breast cancer at diagnosis as established by the
American Joint Committee on Breast Cancer [21] which
consists of 3 components: (i) tumour size (T); (ii)
absence or presence and extent of regional lymph node
metastasis (N); and (iii) absence or presence of distant
metastasis (M).
Outcome assessment
Deaths and recurrences were last updated in June 2009.
Recurrence included a local/regional cancer recurrence,
distant recurrence/metastasis, or development of a con-
tralateral primary breast cancer. Patients who died with-
out recurrence of breast cancer beforehand have been
censored for analysis of recurrence.
The disease free survival (DFS) duration was defined
as the time elapsed between the date of first diagnosis
and the date of first relapse. The overall survival (OS)
duration was the time elapsed between the date of initial
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diagnosis and the date of death or the last status report,
whether the patient was alive or dead, whatever the
cause.
Statistical analyses
Descriptive statistics were calculated for all variables
used in this study and presented as median [range]. OS
and DFS were estimated using Kaplan-Meier method
[22]. A univariate analysis was performed using log rank
methods. Parameters tested to be potentially correlated
with OS or DFS were BMI and WV.
We realized multivariate analysis using Cox’s propor-
tional-hazard models [23] to evaluate the association of
categories of baseline BMI and WV and well defined
pronostic factors in breast cancer with the time to
recurrence and mortality. Covariates considered as
potential confounders in the above model included
menopausal status, tumour stage, nodal involvement,
and treatment after chemotherapy (hormonotherapy).
A p value < 0.05 was considered to be statistically signif-
icant. Variance analysis (Chi2 or Kruskal-Wallis H tests)
was used to test associations between initial BMI, WW
and the covariates. Analyses were conducted using SEM
software version 3.5 [24].
Results
Characteristics of the population
Table 1 lists the main characteristics of patients. The
median age at diagnosis was 54 years (32 - 55 years),
and 55% of the women were post-menopausal at diag-
nosis. In all, 58 patients (52%) had a positive hormone
receptor status and among them 28 were ER+/PR+
(25%). Seventeen percent of the women were diagnosed
with stage I breast cancer while 48% had stage II and
35% had stage III respectively. With regards to tumour
characteristics, 21 patients (19%) were T1, 49 T2 (44%),
17 T3 (15%) and 24 T4 (22%), respectively. Regarding
clinical node involvement, 55 patients were N0 (50%),
49 N1 (44%), 6 N2 (5%) and 1 N3 (1%), respectively.
Treatments
Between 1976 and 1989, patients received a median
number of 6 cycles [2-15] of polychemotherapy. The
median lag time between diagnosis and the start of
treatment was 1.7 months [0-9]. All patients were trea-
ted with an anthracycline-based regimen (AVCF 54%,
AVCFM 44%, FAC 1%, FEC 1%). In all, 66 patients
underwent a tumourectomy and 44 underwent a mas-
tectomy. After chemotherapy, 97% received radiation
and 44% a hormonal therapy (90% with tamoxifen).
BMI and weight variation
The initial median BMI was 24.4 kg/m2 [17.1 - 40.5 kg/
m2]. The different subclasses of patients were distributed
as followed: 9% were underweight, 56% normal, 31%
overweight and 15% obese.
During chemotherapy, weight was stable with a med-
ian relative WV of 0 [-10.9 - 15.4%]. Using a threshold
of 5%, 17% of patients lost weight, 69% were stable and
14% gained weight. Thus, 31% of patients presented a
notable WV, higher than 5%.
Univariate analyses
The median of the follow-up was 20.4 years [19.4 - 27.6].
Among the 111 women, 57 died, 14 developed a local
recurrent, and 56 a distant metastasis. Only few patients
died from other causes than breast cancer. Among the 57
women who died, 47 developed breast cancer recurrence
(83%). No patient was lost of follow-up. The median OS
was 14.3 years [0.7 - 21.8] and median DFS 10 years [0.4
- 21]. The univariate analysis sh owed that OS (p =
0.002) and DFS (p = 0.0039) depended on tumour stage.
We also found that nodal involvement influenced OS
(p < 0.001) and DFS (p = 0.0024).
Concerning the initial BMI, patients with a baseline
BMI of less than 24 kg/m2 had a better OS than those
with an initial BMI of greater than 24 kg/m2 (p = 0.024;
Figure 1A). DFS was also influenced by the BMI, as illu-
strated by a significant statistical difference between
these two groups (p = 0.046; Figure 1B).
Moreover, OS and DFS were influenced by the WV.
As the sample size is likely too small to detect signifi-
cant effects of weight gain or loss as independent fac-
tors, we therefore chose to group women who gained
weight with those who lost weight as a weight changing
group compared to women with no weight variation.
Indeed, a Kaplan-Meier analysis revealed a significant
DFS difference between patients whose weight varied
beyond 5% compared to patients who maintained their
weight (p = 0.048; Figure 2B) while OS analysis was
closed to significance (p = 0.061; Figure 2A).
Variance analysis revealed a significant correlation
between initial BMI and tumour stage (p = 0.0038),
menopausal status (p = 0.00074) but not with clinical
node involvement, hormonotherapy treatment, and
WW. Results from the Chi2 test showed no significant
correlation between weight variation and tumour stage,
nodal involvement, menopausal status, initial BMI and
administration of hormonotherapy after chemotherapy.
Multivariate analysis
The multivariate Cox model (Table 2) included WV,
tumour stage, nodal involvement, initial BMI, menopau-
sal status and treatment by hormonotherapy. As mostly
patients received radiotherapy (97%), this factor was not
included in multivariate analysis.
Only WV still had a significant effect on OS.
A change of weight of more than 5% was associated
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with an increased risk of death of 2.11; 95% CI: 1.21-
3.66 (p = 0.0082).
Moreover, we found that WV was associated with a
risk of recurrence of 2.28; 95% CI: 1.29-4.03 (p =
0.0046). Although DFS was significantly affected by clin-
ical node involvement (p = 0.021). The tumour stage,
initial BMI, menopausal status and treatment by hormo-
notherapy having a significant influence on DFS or on
OS was not observed.
Discussion
In this study, we demonstrate a relationship between
weight variation during polychemotherapy treatment
and both poorer disease-free survival and overall survi-
val after diagnosis of breast cancer.
The present study is in agreement with previous stu-
dies which have found that overweight at the time of
diagnosis increased both breast cancer recurrence and
mortality. This result has been largely demonstrated in
U.S. populations [25-27]. The poorer prognosis of obe-
sity at diagnosis could be explained by the fact that
overweight women tend to be diagnosed with later stage
cancer and therefore more adverse tumour characteris-
tics than normal weight women [28]. For some authors,
this association is restricted to women who detected
their own cancer and not spread amongst cases detected
by either screening mammography or clinical breast
examination [29]. Additionally, lower screening rates
may partly explain the higher breast cancer mortality in
obese women [30]. In agreement with this, in our popu-
lation who were diagnosed 20 years ago, when no
screening mammography was systematically carried out,
we observed a striking association between BMI and
tumour size.
In our series however, with a median WV equal to
zero during chemotherapy treatment of breast cancer
Table 1 Main characteristics of the population study
Characteristics, n = 111 stable weight
(n = 77)
changing weight
(n = 34)
P
Median age (years (range)) 54 (32 – 74) 53 (37 – 70) 54 (32 – 74) 0,49
n (%)
Median BMI 24.4 (17.1 – 40.5) 24.6 (17.1 – 40.5) 24.4 (16.6 – 40.5) 0,14
underweight 9 (8) 7 (9) 2 (6)
normal 56 (50) 36 (47) 20 (59)
overweight 31 (28) 21 (27) 10 (29)
obese 15 (14) 13 (17) 2 (6)
Menopausal status 0,78
Premenopausal 50 (45) 34 (44) 16 (47)
Menopausal 61 (55) 43 (56) 18 (53)
Oestrogene receptors 0,61
Positive 47 (42) 32 (42) 15 (44)
Negative 48 (44) 35 (45) 13 (38)
Progesteron receptors 0,73
Positive 39 (35) 29 (38) 10 (29)
Negative 52 (47) 37 (48) 15 (44)
Tumor stage 0,99
T1 21 (19) 15 (19) 6 (18)
T2 49 (44) 34 (44) 15 (44)
T3 17 (15) 12 (16) 5 (18)
T4 24 (22) 16 (21) 8 (24)
Clinical node involvement 0,34
N0 55 (50) 34 (44) 21 (62)
N1 49 (44) 37 (48) 12 (35)
N2 6 (5) 5 (6) 1 (3)
N3 1 (1) 1 (1)
SBR grade 0,17
I 9 (8) 8 (10) 1 (3)
II 61 (55) 40 (52) 21 (62)
III 22 (20) 8 (10) 4 (12)
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patients, 31% of our population presented a significant
weight variation (> 5%) whereas 68% had maintained
their weight. Our findings of no significant median WV
during chemotherapy treatment are in contrast with the
vast majority of studies conducted in North America,
which have generally reported an average weight gain
ranging from 1.7 to 4.4 kg during the years that follow
diagnosis in women treated by chemotherapy [5,31,32].
On the other hand, one study carried out in a Korean
breast cancer population has already observed a lack of
overall weight gain, with 10.4% of the population gaining
more than 5% of baseline body weight at 1 year [31].
Regarding the baseline mean BMI, we can observe that
populations who did not display a significant weight
gain during chemotherapy treatment, including ours, are
leaner (mean BMI of 24.4 kg/m2 in our study, 23.5 kg/
m2 in Korean study) than the ones used in the U.S. stu-
dies [5] in which the mean BMI varied from to 26.3 to
27.4 kg/m2 [18,32]. Moreover, one possible explanation
is that the chemotherapy regimen administered to our
patients incorporated anthracycline-based therapy as
reported by Han and al. [33], whereas the majority of
the earlier previous studies that observed a weight gain,
involved non-anthracycline-based regimen. Other retro-
spective and prospective reports have not demonstrated
increased weight gain with anthracycline-containing
regimens compared with other regimens [10,11]. Fisher
et al. [34] noted that 14.4% of patients receiving treat-
ment with the AC regimen gained ≥ 5% over pretreat-
ment weight compared with 42.2% of patient receiving
CMF. This result was comparable to our result (14%
gained weight) indeed the fact that patient accrual took
place prior to the widespread use of 5-HT3 receptor
antagonists in the two studies (cancer-related treatment
currently used to reduce the impact of nausea and
emesis associated with anthracycline use).
The long-term follow-up of patients who received
an anthracycline-based chemotherapy in this study
demonstrates that weight variation may not only influ-
ence recurrence, but also patient outcome. In multivari-
ate analysis, clinical node involvement was still
significant, thus, weight change was the strongest
Figure 1 Kaplan-Meier overall survival (OS) (A) and desease-
free survival (DFS) (B) of patients whom initial BMI was < 24
kg/m2 (BMI < 24) and > 24 kg/m2 (BMI > 24).
Figure 2 Kaplan-Meier overall survival (OS) (A) and desease-
free survival (DFS) (B) of patients whom weight variation was
< 5% (stable) and > 5% (changing weight).
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parameter associated with OS and DFS in our series.
Literature on prognostic value of weight variation is
mixed and not easily comparable. These studies that
generally evaluated post-diagnosis weight variation on
different periods which varied from a few months to a
few years after diagnosis, including different treatments
(chemotherapy and or hormonotherapy, radiation
only...), did not use the same prognostic outcomes, and
sometimes with a short median of follow-up. Among
the few studies which evaluated the prognostic value of
weight change after breast cancer diagnosis, four studies
have shown a poor prognosis [8,14-16] whereas five
reported no relationship [9,17-19].
The majority of studies observed an impact of weight
gain on patient outcome. The largest study to date
included 5,204 Nurses’ Health Study participants diag-
nosed with non-metastatic breast cancer between 1976
and 2000 treated with chemotherapy and/or hormonal
therapy [14]. This study reported an increased risk of
recurrence, breast cancer death and total mortality in
patients who gained more than 2 kg/m2 by comparison
to patients who maintained their weight. However this
relationship was found only among women who never
smoked and the definition of recurrence included
reported lung, bone or brain cancer, but excluded any
local recurrences in the ipsilateral breast or new pri-
maries in the contralateral breast. Camoriano et al.
reported weight gain having a significant effect on over-
all survival during treatment with cyclophosphamide,
fluorouracile and prednisolone (CFD) or CFD plus
tamoxifen, but not on recurrence and this only for pre-
menopausal women [8]. Two other studies conducted
prior the common use of anthracycline-based che-
motherapy reported a correlation between weight gain
and overall survival and/or disease-free survival (without
defining which events were included) [15,16].
Only one recent study reported some evidence that
women with early stage breast cancer treated with
chemotherapy and/or radiation and tamoxifen who had
large weight loss (> 10%) were at higher risk of
Table 2 Multivariate Cox model for overall survival (OS) and desease-free survival (DFS)
Category OS DFS
e/n RR 95% – CI P e/n RR 95% – CI P
Weight variation 0.0082* 0.0046*
< 5% (reference) 36/77 1.00 34/77 1.00
> 5% 21/34 2.11 1.21 – 3.66 21/34 2.28 1.29 – 4.03
Clinical Node Involement 0.054 0.021*
N0 (reference) 22/55 1.00 23/55 1.00
N1 30/49 1.61 0.99 – 2.61 27/49 1.78 1.09 – 2.91
N2 4/6 2.59 0.98 – 6.80 4/6 3.18 1.19 – 8.49
N3 1/1 4.16 0.99 – 16.40 1/1 5.66 1.29 – 24.76
Tumor stage 0.084 0.14
T1 (reference) 6/21 1.00 7/21 1.00
T2 24/49 1.32 0.96 – 1.81 25/49 1.17 0.85 – 1.60
T3 10/17 1.74 0.93 – 3.27 7/17 1.37 0.73 – 2.57
T4 17/24 2.30 0.90 – 5.90 16/24 1.60 0.60 – 4.13
Initial BMI 0.20 0.33
< 24 kg/m2 21/52 1.00 21/52 1.00
≥ 24 kg/m2 36/59 1.49 0.81 – 2.74 34/59 1.59 0.86 – 2.93
Menopausal status 0.79 0.46
Premenopausal (reference) 21/50 1.00 23/50 1.00
Menopausal 36/61 1.09 0.59 – 1.99 32/61 0.96 0.53 – 1.76
Hormonotherapy 0.81 0.90
no (reference) 34/67 1.00 36/67 1.00
yes 23/44 0.93 0.53 – 1.65 19/14 0.80 0.44 – 1.14
* P value considered statistically significant (p < 0.05).
All the variable in the table were mutually adjusted for each other.
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recurrence and death compared to women with no
weight variation. This elevated risk was more pro-
nounced among women who were obese before diagno-
sis or who had ER- or PR- tumours [19]. One obvious
explanation for significant weight loss being related to
an increased risk of death could be that the breast can-
cer disease process itself caused weight loss.
Literature on the prognostic value of weight variation
reported some evidence that women who had gained or
lost weight have a higher risk of recurrence and death
compared to women with no weight variation. So, we
chose to group women who gained weight with those
who lost weight as a weight changing group. We
hypothesized that weight change reflected a metabolic
disorder by comparison to women who maintained their
weight with an energy balance in equilibrium (Figure 3).
Chemotherapy induced a decrease in energy expenditure
(lowered basal metabolic rate, thermogenesis, and physi-
cal activity [4]) and different modifications in dietary
intake (increase in appetite [14] or decreased ingestion
of food due to chemotherapy related nausea and emesis)
that can lead to weight gain or loss according to dietary
behaviour of patient. Moreover, women with breast can-
cer receiving adjuvant chemotherapy underwent unfa-
vourable changes in body composition with lean body
loss due to a negative nitrogen balance [35] even in the
absence of an overall weight change [4]. A lot of data
has demonstrated that weight gain during chemotherapy
was indicative of sarcopenic obesity [33]. Indeed, che-
motherapy for breast cancer like taxane and anthracy-
cline can increase inflammation [36,37] which played a
central role on different modifications induced by che-
motherapy. Inflammatory cytokines interfered with the
satiety centre [38] and catabolism of skeletal muscle
protein responsive of sarcopenia but not independently
of any of the considered obesity indexes [39].
Several mechanisms have been proposed to explain
the adverse effect of weight gain on risk of recurrence
and mortality. First, weight gain and all associated meta-
bolic disorders may predispose women to diabetes or
heart disease, thereby predisposing them to morbidity
and mortality [6]. However, in our study, only a few
patients died from causes other than breast cancer
(14%). One possible mechanism was a greater aromatase
activity in the excess adipose tissue [40] and an inhibi-
tion of synthesis of sex hormone-binding globuline asso-
ciated with an increased in free estradiol level which
stimulates neoplasic cells [41].
Insulin resistance may be a common mechanism to
explain the poor prognosis of patients who experienced
a weight loss or a weight gain (Figure 3). Indeed, insulin
resistance has been shown in variety of cancer patients
with body-weight loss [42], but was also seen in over-
weight women [43]. Fasting serum insulin concentration
has been directly associated with an increase in both
distant recurrence and death in women previously trea-
ted for breast cancer [42,43]. There is a strong biological
rational for an adverse prognostic effect of insulin. Insu-
lin, a member of a family of growth factors that includes
IGF-I and IGF-II, exerts a mitogenic effect on malignant
breast cancer cells though IGF-I receptor. It is also
hypothesized that visceral obesity increases both insulin-
like growth factors (IGF-I, IGF-II) which stimulates the
synthesis of sex steroid hormones [31] that are involved
in the regulation of normal and malignant growth of
epithelial breast cells. Several studies have reported a
reduction in circulating concentration of IGF-I in malig-
nant disease, which may also have been associated with
nutritional decline and systemic inflammation [44].
Yoshikawa et al. hypothesized that inflammatory reac-
tions might be involved in the development of insulin
resistance [42]. Moreover, few studies reported an asso-
ciation between elevated inflammatory cytokines and a
worse prognosis in breast cancer patients [45,46].
Further research is needed to understand the biologi-
cal mechanisms underlying the relationship between
weight variation and breast cancer growth with explora-
tion of insulin resistance in association with body com-
position, measurement of energy expenditures, calorie
intake and inflammatory reaction.
Figure 3 Possible mechanisms to explain weight change
during chemotherapy treatment of non metastatic breast
cancer and its prognostic value.
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The current study had several limitations including its
study design (retrospective chart review) and a relatively
small sample size to draw a conclusion on the indepen-
dent effect of weight variation. Some interesting covari-
ates like “normal “ weight prior diagnosis, smoking
status, physical activity or sociodemographic aspects
(education) have not been explored because of the lack
of this data in patients’ medical records. Additionally,
more detailed measurement of body shape and fat con-
tent are lacking. Currently a long-term measurement of
weight during patient follow-up is ongoing and could
offer the possibility to explore weight variation after
treatment which could also affect prognostic outcomes.
Conclusions
Our results suggest that weight change during anthracy-
cline-based treatment of early stage breast cancer is
associated with increased risk of recurrence and poorer
survival, though they may require additional confirma-
tion. Furthermore, while we have speculated on poten-
tial biological targets, more research is needed to
understand the biological mechanisms underlying the
relationship between weight variation and breast cancer
growth.
Abbreviations
WV: weight variation; BMI: Body Mass Index; TNM: tumor-node-metastasis;
DFS: disease free survival; OS: overall survival; CI: confidence Interval.
Acknowledgements and funding
The Authors thank Delphine Roux and Delphine Crouzet for acquisition of
data, and David Belin for copyedit the paper.
Author details
1Division of Clinical Research, Centre Jean Perrin, Clermont-Ferrand, F-63011
France; University Clermont 1, UFR Médecine, Clermont-Ferrand, F-63001
France; Centre d’Investigation Clinique, Clermont-Ferrand, F-63001 France.
2UMR 990 INSERM/UdA, Clermont-Ferrand, F-63000 France. 3Oncology
department, Centre Jean Perrin, Clermont-Ferrand, F-63011 France; University
Clermont 1, UFR Médecine, Clermont-Ferrand, F-63001 France; Centre
d’Investigation Clinique, Clermont-Ferrand, F-63001 France. 4Surgery
department, Centre Jean Perrin, Clermont-Ferrand, F-63011 France; University
Clermont 1, UFR Médecine, Clermont-Ferrand, F-63001 France; Centre
d’Investigation Clinique, Clermont-Ferrand, F-63001 France.
Authors’ contributions
ET contributed to the data collection, analysis and wrote the paper. ST and
OL contributed to the data collection and helped in in writing the final
draft. FK contributed to the data analysis. EG, CA, EP helped in writing the
final draft. PG, MAMR, PC and XD contributed to patient recruitment. PC and
XD contributed to the study design and analysis and have been involved in
drafting the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 December 2009 Accepted: 25 November 2010
Published: 25 November 2010
References
1. NIH Consens Statement: Adjuvant therapy for Breast Cancer 2000, 17:1-35.
2. Carmichael AR: Obesity and prognosis of breast cancer. Obesity reviews:
an official journal of the International Association for the Study of Obesity
2006, 7:333-340.
3. Goodwin PJ, Esplen MJ, Wincour J, Butler K, Pritchard KI: Development of a
weight management program in women with newly diagnosed
locoregional breast cancer. In Pschosomatic Obstetrics and Gynecology.
Edited by: Bitzer J, Stauber M. Bologna: Monduzzi Editore, International
Proceedings Division; 1995:491-496.
4. Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK,
Blackwell K, Rimer BK: Changes in weight, body composition, and factors
influencing energy balance among premenopausal breast cancer
patients receiving adjuvant chemotherapy. J Clin Oncol 2001,
19:2381-2389.
5. Saquib N, Flatt SW, Natarajan L, Thomson CA, Bardwell WA, Caan B,
Rock CL, Pierce JP: Weight gain and recovery of pre-cancer weight after
breast cancer treatments: evidence from the women’s healthy eating
and living (WHEL) study. Breast Cancer Res Treat 2007, 105:177-186.
6. Demark-Wahnefried W, Winer EP, Rimer BK: Why women gain weight with
adjuvant chemotherapy for breast cancer. J Clin Oncol 1993,
11:1418-1429.
7. Demark-Wahnefried W, Rimer BK, Winer EP: Weight gain in women
diagnosed with breast cancer. J Am Diet Assoc 1997, 97:519-526, 529; quiz
527-528.
8. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH:
Weight change in women treated with adjuvant therapy or observed
following mastectomy for node-positive breast cancer. J Clin Oncol 1990,
8:1327-1334.
9. Goodwin PJ, Panzarella T, Boyd NF: Weight gain in women with localized
breast cancer–a descriptive study. Breast Cancer Res Treat 1988, 11:59-66.
10. Levine EG, Raczynski JM, Carpenter JT: Weight gain with breast cancer
adjuvant treatment. Cancer 1991, 67:1954-1959.
11. Makari-Judson G, Judson CH, Mertens WC: Longitudinal patterns of weight
gain after breast cancer diagnosis: observations beyond the first year.
Breast J 2007, 13:258-265.
12. Rock CL, Demark-Wahnefried W: Nutrition and survival after the diagnosis
of breast cancer: a review of the evidence. J Clin Oncol 2002,
20:3302-3316.
13. Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS: Weight change during
chemotherapy as a potential prognostic factor for stage III epithelial
ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol
2007, 2:260-265.
14. Kroenke CH, Chen WY, Rosner B, Holmes MD: Weight, weight gain, and
survival after breast cancer diagnosis. J Clin Oncol 2005, 23:1370-1378.
15. Bonomi PBN, Fishman D: Weight gain during breast cancer evaluated in
relation to disease-free survival (DFS). Breast Cancer Research And
Treatment 1984, 4:339.
16. Chlebowski RT, Weiner JM, Reynolds R, Luce J, Bulcavage L, Bateman JR:
Long-term survival following relapse after 5-FU but not CMF adjuvant
breast cancer therapy. Breast Cancer Res Treat 1986, 7:23-30.
17. Heasman KZ, Sutherland HJ, Campbell JA, Elhakim T, Boyd NF: Weight gain
during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat
1985, 5:195-200.
18. Caan BJ, Kwan ML, Hartzell G, Castillo A, Slattery ML, Sternfeld B, Weltzien E:
Pre-diagnosis body mass index, post-diagnosis weight change, and
prognosis among women with early stage breast cancer. Cancer Causes
Control 2008, 19:1319-1328.
19. Caan BJ, Emond JA, Natarajan L, Castillo A, Gunderson EP, Habel L, Jones L,
Newman VA, Rock CL, Slattery ML, Stefanick ML, Sternfeld B, Thomson CA,
Pierce JP: Post-diagnosis weight gain and breast cancer recurrence in
women with early stage breast cancer. Breast Cancer Res Treat 2006,
99:47-57.
20. Marret H, Perrotin F, Bougnoux P, Descamps P, Hubert B, Lefranc T, Le
Floch O, Lansac J, Body G: Low body mass index is an independent
predictive factor of local recurrence after conservative treatment for
breast cancer. Breast Cancer Res Treat 2001, 66:17-23.
21. Sobin LHWC: TNM Classification of Malignant Tumours. New York, NY:
UICC, Wiley-Liss; 2002.
22. Kaplan ELMP: Non Parametric estimation for incomplete observations. J
Am Stat Assoc 1958, 53:457-481.
23. Cox DR: Regression Models and Life-Tables. Journal of the Royal
Statistical Society. Series B (Methodological) 1972, 34:187-220.
Thivat et al. BMC Cancer 2010, 10:648
http://www.biomedcentral.com/1471-2407/10/648
Page 8 of 9
24. Kwiatkowski F, Girard M, Hacene K, Berlie J: Sem: a suitable statistical
software adaptated for research in oncology. Bull Cancer 2000,
87:715-721.
25. Pierce JP, Stefanick ML, Flatt SW, Natarajan L, Sternfeld B, Madlensky L, Al-
Delaimy WK, Thomson CA, Kealey S, Hajek R, Parker BA, Newman VA,
Caan B, Rock CL: Greater survival after breast cancer in physically active
women with high vegetable-fruit intake regardless of obesity. J Clin
Oncol 2007, 25:2345-2351.
26. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL:
Relation of body mass index to tumor markers and survival among
young women with invasive ductal breast carcinoma. Cancer 2001,
92:720-729.
27. Chlebowski RT, Aiello E, McTiernan A: Weight loss in breast cancer patient
management. J Clin Oncol 2002, 20:1128-1143.
28. Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL: Body
mass and stage of breast cancer at diagnosis. Int J Cancer 2002,
98:279-283.
29. Reeves MJ, Newcomb PA, Remington PL, Marcus PM, MacKenzie WR: Body
mass and breast cancer. Relationship between method of detection and
stage of disease. Cancer 1996, 77:301-307.
30. Maruthur NM, Bolen S, Brancati FL, Clark JM: Obesity and mammography:
a systematic review and meta-analysis. J Gen Intern Med 2009, 24:665-677.
31. Demark-Wahnefried W, Rock CL: Nutrition-related issues for the breast
cancer survivor. Semin Oncol 2003, 30:789-798.
32. Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L,
Gilliland FD, Ballard-Barbash R: Changes in body fat and weight after a
breast cancer diagnosis: influence of demographic, prognostic, and
lifestyle factors. J Clin Oncol 2005, 23:774-782.
33. Han HS, Lee KW, Kim JH, Kim SW, Kim IA, Oh DY, Im SA, Bang SM, Lee JS:
Weight changes after adjuvant treatment in Korean women with early
breast cancer. Breast Cancer Res Treat 2009, 114:147-153.
34. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG,
Bowman D, Wolmark N, Wickerham DL, Kardinal CG, et al: Two months of
doxorubicin-cyclophosphamide with and without interval reinduction
therapy compared with 6 months of cyclophosphamide, methotrexate,
and fluorouracil in positive-node breast cancer patients with tamoxifen-
nonresponsive tumors: results from the National Surgical Adjuvant
Breast and Bowel Project B-15. J Clin Oncol 1990, 8:1483-1496.
35. Gudny Geirsdottir O, Thorsdottir I: Nutritional status of cancer patients in
chemotherapy; dietary intake, nitrogen balance and screening. Food Nutr
Res 2008, 52:10, 3402/fnr.v52i0.1856.
36. Mills PJ, Ancoli-Israel S, Parker B, Natarajan L, Hong S, Jain S, Sadler GR, von
Känel R: Predictors of inflammation in response to anthracycline-based
chemotherapy for breast cancer. Brain Behav Immun 2008, 22:98-104.
37. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D: Immune
changes in patients with advanced breast cancer undergoing
chemotherapy with taxanes. Br J Cancer 2002, 87:21-27.
38. Durham WJ, Dillon EL, Sheffield-Moore M: Inflammatory burden and
amino acid metabolism in cancer cachexia. Curr Opin Clin Nutr Metab
Care 2009, 12:72-77.
39. Cesari M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BW,
Lenchik L, Palla SL, Ambrosius WT, Tracy RP, Pahor M: Sarcopenia, obesity,
and inflammation - results from the Trial of Angiotensin Converting
Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin
Nutr 2005, 82:428-434.
40. Loi S, Milne RL, Friedlander ML, McCredie MR, Giles GG, Hopper JL,
Phillips KA: Obesity and outcomes in premenopausal and
postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2005,
14:1686-1691.
41. Kaye SA, Folsom AR, Soler JT, Prineas RJ, Potter JD: Associations of body
mass and fat distribution with sex hormone concentrations in
postmenopausal women. Int J Epidemiol 1991, 20:151-156.
42. Yoshikawa T, Noguchi Y, Doi C, Makino T, Nomura K: Insulin resistance in
patients with cancer: relationships with tumor site, tumor stage, body-
weight loss, acute-phase response, and energy expenditure. Nutrition
2001, 17:590-593.
43. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y,
Hartwick W, Hoffman B, Hood N: Fasting insulin and outcome in early-
stage breast cancer: results of a prospective cohort study. J Clin Oncol
2002, 20:42-51.
44. Simons JP, Schols AM, Buurman WA, Wouters EF: Weight loss and low
body cell mass in males with lung cancer: relationship with systemic
inflammation, acute-phase response, resting energy expenditure, and
catabolic and anabolic hormones. Clin Sci (Lond) 1999, 97:215-223.
45. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML,
Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A,
Ulrich CM: Elevated biomarkers of inflammation are associated with
reduced survival among breast cancer patients. J Clin Oncol 2009,
27:3437-3444.
46. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420:860-867.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/648/prepub
doi:10.1186/1471-2407-10-648
Cite this article as: Thivat et al.: Weight change during chemotherapy
changes the prognosis in non metastatic breast cancer for the worse.
BMC Cancer 2010 10:648.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thivat et al. BMC Cancer 2010, 10:648
http://www.biomedcentral.com/1471-2407/10/648
Page 9 of 9
